Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK2 | P19525 | 2/20 | 0.50 |
| ▸ | GSK3B | P49841 | 6/20 | 0.45 |
| ▸ | IKBKB | O14920 | 3/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 5/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5890132 | 0.92 | EIF2AK2 (0.49) | EIF2AK2GSK3BIKBKBMAPK10MAPK8 | |
| SCHEMBL5890058 | 0.91 | EIF2AK2 (0.49) | EIF2AK2GSK3BIKBKBMAPK10MAPK8 | |
| SCHEMBL5890754 | 0.91 | EIF2AK2 (0.49) | EIF2AK2GSK3BIKBKBMAPK10MAPK8 | |
| SCHEMBL6105006 | 0.89 | GSK3B (0.49) | EIF2AK2GSK3BIKBKBMAPK10MAPK8 | |
| SCHEMBL5890649 | 0.88 | CSNK1D (0.51) | EIF2AK2GSK3BIKBKBMAPK10MAPK8 | |
| SCHEMBL5220849 | 0.88 | EIF2AK2 (0.50) | EIF2AK2GSK3BIKBKBMAPK10MAPK8 | |
| SCHEMBL6105383 | 0.85 | GSK3B (0.50) | EIF2AK2GSK3BIKBKBMAPK10MAPK8 | |
| SCHEMBL6105305 | 0.85 | EIF2AK2 (0.51) | EIF2AK2GSK3BMAPK10PIK3CAPIK3CB | |
| SCHEMBL5890384 | 0.84 | ADORA1 (0.48) | EIF2AK2GSK3BIKBKBMAPK10MAPK8 | |
| SCHEMBL5453019 | 0.84 | EIF2AK2 (0.50) | EIF2AK2GSK3BIKBKBMAPK10CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962914-B2 | Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2005-11-08 | — | — | US | claimed |
| EP-1385847-B1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES | SMITHKLINE BEECHAM CORP (US) | 2005-06-01 | — | — | EP | claimed |
| US-20040142941-A1 | Therapeutic compounds | SMITHKLINE BEECHAM CORPORATION | 2004-07-22 | — | — | US | claimed |
| US-7030134-B2 | Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-18 | — | — | US | disclosed |
| US-6962914-B2 | Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050192303-A1 | Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds | GUDMUNDSSON KRISTJAN (US) | 2005-09-01 | — | — | US | disclosed |
| EP-1385847-B1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES | SMITHKLINE BEECHAM CORP (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040142941-A1 | Therapeutic compounds | SMITHKLINE BEECHAM CORPORATION | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142941-A1 | Therapeutic compounds | PCSK9, ABCB1, ABCB11 | EIF2AK2 3551/4885GSK3B 1245/4885IKBKB 1569/4885 |
| US-20050192303-A1 | Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds | DPYD, TYMP, P2RY4 | EIF2AK2 1588/4885GSK3B 2173/4885IKBKB 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.